Salix Pharmaceuticals, Ltd. (SLXP) Reports Digestive Disease Week Update; XIFAXAN Investigated In Pouchitis 
10/19/2005 5:10:05 PM

RALEIGH, N.C.--(BUSINESS WIRE)--May 16, 2005--Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today reported results of an investigator-initiated trial of XIFAXAN(TM) (rifaximin) tablets 200 mg that are being presented at Digestive Disease Week(R) 2005 (DDW) today. The poster is available for viewing from 8:00 a.m. until 5:00 p.m. today. The investigator has been requested to be present at the poster from 12:00 noon until 2:00 p.m. Pouchitis Dr. Leonard Baidoo, Graduate Hospital, Philadelphia, PA, et al. investigated the efficacy, tolerability and safety profile of rifaximin 800 mg daily (400 mg BID) in the treatment of 10 patients experiencing pouchitis. In this open label study patients were treated with 400 mg of rifaximin two times daily for 14 days. 90% of the patients responded to treatment with rifaximin, with mean time to onset of response of 3 days and mean time to complete response of 7 days. 89% of the responders, including 3 patients who had been refractory to treatment with ciprofloxacin dosed at 500 mg two times daily, had complete remission and 11% reported a greater than 50% response. Mean bowel frequency decreased from 14 daily to 5 daily. All patients reported decreased fecal urgency and complete resolution of abdominal pain. No adverse events were reported.